Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04324164

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Non-small Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Yongchang Zhang

Changsha, Hunan, 410013, China

Location status: Recruiting

Location contact

Yongchang Zhang, MD

CONTACT

[email protected]

+8613873123436 ext. +8613873123436

About this study

Inclusion criteria

Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
  • Uncommon EGFR Mutant Advanced NSCLC

Exclusion criteria

  • Patients with contraindication of chemotherapy
  • Pregnant or breast feeding women

Treatment and study plan

Third-generation EGFR-TKI

Drug

Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

EGFR-TKI

Drug

All EGFR-TKI

Primary outcomes

  1. PFS

    Time frame: 5 years

    Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

Secondary outcomes

  1. OS

    Time frame: 5 years

    Defined as the time from the start of treatment to the death of the subject due to any cause.

  2. ORR

    Time frame: 5 years

    Defined as the proportion of subjects achieving a complete remission (CR) or partial remission (PR) among all subjects.

Study contacts

Contact information is provided by the study sponsor or research team.

Nong Yang, MD

CONTACT

[email protected]

+8613055193557 ext. +8613873123436

Yongchang Zhang, MD

CONTACT

[email protected]

+8613873123436 ext. 7+861383123436

Sponsors and collaborators

Lead sponsor

Hunan Province Tumor Hospital

Other

Registry information

Official study title

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Important dates

Study start
2020
Primary completion
2025
Study completion
2027
First posted
Mar 27, 2020
Registry last updated
Jan 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.